According to a new report from the USA's Institute of Medicine, the Food and Drug Administration relies on crude tools to measure the benefits of drugs, food and supplements, and needs a whole new set of standards. It has therefore recommended that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process to evaluate studies that are presented by companies seeking product approvals.
There are no scientific grounds for using different standards of evidence when evaluating the health benefits of food ingredients and drugs given that both can have significant impacts on people's well-being, said the committee that wrote the report.
Congress should boost FDA's authority
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze